EUNETWORKS-FIBER-UK-LTD.
euNetworks Fiber UK Limited (“euNetworks”), a Western European bandwidth infrastructure company, has deployed a new ultra low latency route between Basildon and London in the UK that connects the ICE data centre to Interxion LON1 & 2: A Digital Realty Company, and onwards to Slough. These are critical locations for financial markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220921005083/en/
Paula Cogan, President euNetworks (Photo: Business Wire)
The new route is over 45km long and includes 14km of ultra low latency CoreSmart® cable. Lumenisity® Limited (“Lumenisity”) supplied the award-winning CoreSmart cable, which is based on NANF® hollowcore technology to enable transmission over long distances and is compatible with regular single mode fibre – both major constraints on other hollowcore fibre architectures. The route is the longest commercial deployment of hollowcore fibre technology to date and its use is exclusive to euNetworks and its customers. It is also the first commercial construction of a long distance hybrid route of hollowcore fibre and regular single mode fibre.
Offering euNetworks’ dedicated network platform euTrade, at bandwidths between 1G and 10G, this hybrid route is 10% faster than an equivalent all single mode fibre cable. It’s the third deployment for euNetworks following successful deliveries of the first hollowcore fibre based commercial route in April 2021 and the second in March earlier this year.
“We have successfully delivered increasingly longer deployments of hollowcore fibre in our network, becoming the first fibre provider in the world to utilise the benefits of this new fibre technology in commercial markets,” said Paula Cogan, President of euNetworks. “From the initial 1km pilot, the teams have gone on to deploy hollowcore cable lengths of 7km and 14km on our network, as well as successfully blending hollowcore fibre with regular single mode fibre on this latest route. We continue to be focused on delivering the best possible bandwidth solutions for our customers and look forward to deploying longer routes with Lumenisity in the coming quarters. Leading the market in fibre-based ultra low latency services throughout Europe remains a key focus for euNetworks.”
“We are pleased to partner with euNetworks again, successfully deploying this new route and achieving this hollowcore cable link length”, said Tony Pearson, VP Sales & Marketing at Lumenisity. “We are excited to reach this milestone with euNetworks, and will continue to deliver a unique cable solution offering longer reach and lower latency for their customers.”
Data travels 50% faster in hollowcore cable, reducing latency by 33%, and providing a round trip saving of 3μs (three microseconds) per kilometre. These latency savings are hugely significant in financial trading applications. They can also be scaled to increase the separation of data centres by 50%, whilst maintaining the latency envelope, more than doubling the area of land in which these data centres can be located.
euNetworks’ euTrade solution is a dedicated network platform supporting the bandwidth needs of the financial services community. The company continues to optimise routes between all the key trading exchanges in Europe, and is supporting major exchange moves this year. This focus ensures delivery of the shortest paths and lowest latencies available in the market.
About euNetworks
euNetworks is a critical bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 53 cities in 17 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 480 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com.
About Lumenisity® Limited
Lumenisity is an established independent company originally spun out from the world-renowned Optoelectronics Research Centre (ORC) at the University of Southampton. Formed in 2017 to commercialise breakthroughs in the development of hollowcore optical fibre at the ORC, the company has built a team of industry leaders and experts to realise their goal to be the world’s premier high-performance hollowcore fibre optic cable solutions provider offering their customers reliable, deployable, low latency and high bandwidth connections that unlock new capabilities in communication networks. Lumenisity®, NANF® and Coresmart® are registered trademarks of Lumenisity Limited.
Visit our website at: www.lumenisity.com and visit the team on booth 369 at the ECOC 2022 Exhibition in Basel (19th – 21st September) to find out more about our hollowcore cable solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005083/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom